A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

Background Trifluridine/tipiracil (FTD/TPI) improved the overall survival in patients with metastatic colorectal cancer (mCRC) who had previously received standard chemotherapies; however, the clinical outcomes remain poor. Objective A multicenter phase II study aimed to assess the efficacy and safe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Targeted oncology 2023-05, Vol.18 (3), p.369-381
Hauptverfasser: Izawa, Naoki, Masuishi, Toshiki, Takahashi, Naoki, Shoji, Hirokazu, Yamamoto, Yoshiyuki, Matsumoto, Toshihiko, Sugiyama, Keiji, Kajiwara, Takeshi, Kawakami, Kentaro, Aomatsu, Naoki, Kondoh, Chihiro, Kawakami, Hisato, Takegawa, Naoki, Esaki, Taito, Shimokawa, Mototsugu, Nishio, Kazuto, Narita, Yukiya, Hara, Hiroki, Sunakawa, Yu, Boku, Narikazu, Moriwaki, Toshikazu, Eguchi Nakajima, Takako, Muro, Kei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!